Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1755-3768.1969.tb05613.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The prophylactic application of low-dose rabbit antithymocyte globulin in matched siblings HSCT with high-risk factors for graft-versus-host disease.
Transpl Immunol
December 2024
Department of Hematology, The 960th Hospital of The Chinese People's Liberation Army Joint Logistics Support Force, Jinan, China. Electronic address:
Article Synopsis
- Relapse and graft-versus-host disease (GVHD) are major causes of death after allogeneic hematopoietic stem cell transplantation (allo-HSCT), with antithymocyte globulin (ATG) being debated for its role in preventing GVHD, particularly in matched sibling HSCT cases.
- A retrospective study from January 2018 to June 2023 found that patients receiving ATG had significantly lower rates of both acute GVHD (30% vs. 81.8%) and chronic GVHD (20% vs. 72.7%) compared to those not receiving ATG.
- Importantly, the use of ATG did not significantly affect disease relapse, infection rates, or survival outcomes
Allogeneic Hematopoietic Cell Transplantation for the Treatment of Severe Aplastic Anemia: Evidence-Based Guidelines From the American Society for Transplantation and Cellular Therapy.
Transplant Cell Ther
December 2024
Dana-Farber Cancer Institute/Brigham and Women's Hospital, Boston, Massachusetts.
Article Synopsis
- * A panel of experts made recommendations emphasizing the use of bone marrow as a graft source and preferred rabbit antithymocyte globulin over horse ATG for conditioning. They also support using fludarabine for high-risk patients and expanding HCT eligibility to fit older adults.
- * The panel advocates prioritizing matched unrelated or haploidentical donor transplants over immunosuppressive therapy when a matched related donor isn't available and suggests specific GVHD prophylaxis options for donor
ATG-Thymoglobulin Versus ATG-Fresenius for Conditioning in Thalassemia Patients Who Underwent Allogenic Stem Cell Transplantation from Matched-Sibling Donor: A Tertiary Cancer Care Center Short-Term Experience.
Hemoglobin
May 2024
Department of Hematology and Bone Marrow Transplant Unit, Rajiv Gandhi Cancer Institute and Research Centre, Delhi, India.
Graft rejection and Graft-versus-host disease (GVHD) are some of the significant factors resulting in morbidity and mortality following allogeneic hematopoietic cell transplantation. Prophylaxis for GVHD using T-cell depleting agents is helpful in reducing the transplant-related mortality and graft rejection. Both tATG and fATG exhibit varied amounts of antibody specificities and perform distinct immunomodulatory effects, regardless of their capacity to deplete T-lymphocytes.
View Article and Find Full Text PDF[Acquired severe aplastic anemia in emerging countries: Management from allogeneic hematopoietic cell transplantation indication until post-transplant follow-up SFGM-TC].
Bull Cancer
January 2025
Service d'hématologie et greffe, hôpital Cheikh-Zaïd universitaire international, cité Al-Irfane-Hay Ryad, avenue Allal-al-Fassi, 10000 Rabat, Maroc.
Management of acquired aplastic anemia (AA) in emerging countries depends on the means of prognostic stratification, treatment and logistics available. During the 13th annual harmonization workshop of the francophone Society of bone marrow transplantation and cellular therapy (SFGM-TC), a designated working group reviewed the literature in order to elaborate unified guidelines for allogeneic hematopoietic cell transplantation (Allo-HCT) in this disease. In terms of practice, the conclusions are as follows; The use of anti-tymocyte globuline (ATG) is mainly from rabbit and very little from horse.
View Article and Find Full Text PDFComparison of hematopoietic stem cell transplantation and repeated intensified immunosuppressive therapy as second-line treatment for relapsed/refractory severe aplastic anemia.
Front Immunol
September 2024
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Article Synopsis
- A study compared the effectiveness of allogeneic hematopoietic stem cell transplantation (allo-HSCT) with repeated immunosuppressive therapy (IST) for patients with severe aplastic anemia (SAA) who did not respond to initial treatment, finding a 57.6% overall response rate in the IST group and high hematologic recovery in the HSCT group.
- All patients in the HSCT group achieved neutrophil engraftment with no primary graft failures, while the cumulative incidences of acute and chronic graft-versus-host disease (GVHD) indicated some degree of complications, but overall survival rates were similar between the two groups.
- The results suggested that younger patients
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!